Companies › Norgine
1 active drug program in 1 registered trial: 1 Phase 3; Gastroenterology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PLENVU® (NER1006) Polyethylene glycol (PEG)-based bowel cleansing agent | – | Phase 3 | Bowel Cleansing Prior to Clinical Procedures | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07218523 | PLENVU® (NER1006) | Phase 3 | Bowel Cleansing Prior to Clinical Procedures | Gastroenterology | Jan 2027 |
No annotated target.
–
Elgan Pharma Cinclus Pharma Holding Green Cross Wellbeing Inventiva Pharma Dr. Falk Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.